Answers are grounded in this paper and cite their sources.
The author comments on a report in this issue of Cancer by investigators who used clinical response endpoints and chemoresistance testing to confirm the improved survival of women with hereditary ovarian carcinoma compared with women who had sporadic ovarian carcinoma. The possible use of BRCA mutation status to improve patient care, the future of translational research, and the difficulties in proceeding with large‐scale prospective trials are among the topics discussed. See also pages 2187–95.
No takes yet. Share an insight, caveat, or question.
Stephen C. Rubin (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: